K
Kenneth J. Pienta
Researcher at Johns Hopkins University School of Medicine
Publications - 751
Citations - 72579
Kenneth J. Pienta is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 127, co-authored 671 publications receiving 64531 citations. Previous affiliations of Kenneth J. Pienta include Rutgers University & Harper University Hospital.
Papers
More filters
Journal ArticleDOI
A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer
TL;DR: Diethylstilbesterol appears to be an active agent for second-line hormone therapy for metastatic prostate cancer and should be considered for development under the orphan drug strategy.
Journal ArticleDOI
Natural BH3 mimetic (-)-gossypol chemosensitizes human prostate cancer via Bcl-xL inhibition accompanied by increase of Puma and Noxa
Yang Meng,Wenhua Tang,Yao Dai,Xiaoqing Wu,Meilan Liu,Qing Ji,Min Ji,Kenneth J. Pienta,Theodore Lawrence,Liang Xu +9 more
TL;DR: Data suggest that (-)-gossypol significantly enhances the antitumor activity of chemotherapy in vitro and in vivo, representing a promising new regime for the treatment of human hormone-refractory prostate cancer with Bcl-2/Bcl-xL/Mcl-1 overexpression.
Journal ArticleDOI
E-cadherin expression in prostate cancer: a broad survey using high-density tissue microarray technology.
TL;DR: The findings of this study are most consistent with a transient down-regulation of E-cadherin in localized prostate cancer.
Journal ArticleDOI
MIM, a Potential Metastasis Suppressor Gene in Bladder Cancer
TL;DR: Using a modified version of the mRNA differential display technique, five human bladder cancer cell lines from low grade to metastatic were analyzed and a gene that was not expressed in the metastatic cell line TccSuP was isolated and named Missing in Metastasis (MIM).
Journal ArticleDOI
Advances in prostate cancer chemotherapy : A new era begins
Kenneth J. Pienta,David Smith +1 more
TL;DR: Two landmark studies demonstrated a survival advantage in androgen‐independent prostate cancer patients utilizing docetaxel chemotherapy, setting a new standard of care for this disease.